Skip to content

Understanding of Psychotic Disorders in Children With 22q11.2DS

Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04639388
Acronym
PremiCeS22
Enrollment
80
Registered
2020-11-20
Start date
2020-11-13
Completion date
2026-09-30
Last updated
2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

22q11.2 Deletion Syndrome

Brief summary

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

Detailed description

22q11.2DS is one of the most common microdeletion syndromes (1 / 2000-1 / 4000 births) and one of the most robust genetic risk factors for schizophrenia (1 to 2% of cases). Reciprocally, approximately 30% of patients with 22q11.2DS will develop psychotic symptoms in adolescence or early adulthood. It is now well established that children and adults with 22q11.2DS have lower social skills than developing youth. These social dysfunctions could be partly underpinned by alterations in social cognitive processes, and could also be linked to the emergence of psychotic signs or even schizophrenia. However, to our knowledge, no study has investigated the existence of behavioral prodromal signs during the onset of psychotic signs in children with 22q11.2DS. In addition, the origin of social cognitive processes remains to this day little explored.

Interventions

BEHAVIORALneuropsychological testing, questionnaires and experimental tasks

Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition

Sponsors

Hôpital le Vinatier
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Monocentric study with two parallel groups

Eligibility

Sex/Gender
ALL
Age
4 Years to 13 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of 22q11.2 deletion syndrome or no developmental disease * Aged from 4 to 13 years old * French language

Exclusion criteria

* Diagnosis of intellectual deficiency according to DSM 5 criteria * Drug prescribed for somatic condition that could influence cerebral functioning

Design outcomes

Primary

MeasureTime frameDescription
The Screen for child Anxiety Related Emotional Disorders (SCARED)Day 1Scale assessing behavioral prodromes or warning signs of hallucinations in psychotic disorders A psychometric study is then carried out on this questionnaire in order to validate it with parents of children carrying 22q11.2DS.
facial expression recognition taskDay 1Proportion of correct responses in experimental tasks evaluating gaze direction and facial expression recognition

Secondary

MeasureTime frameDescription
Sustained hearing attention test (Tea-Ch battery)Day 1Proportion of impaired scaled score at the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch)
Rey's Tangled Lines TestDay 1Proportion of impaired scaled score to study the degree of cognitive development in children
NEPSY II batteryDay 1Proportion of impaired scaled score at auditory attention of NEPSY II battery The NEPSY-II is a comprehensive neuropsychological battery for children ages 3-12. The test provides measures of sensor-motor, language, visuospatial processing, memory and learning, attention/executive functions, and social cognition.
Mean reaction timeDay 1Mean reaction time in neuropsychological testing and experimental tasks

Countries

France

Contacts

Primary ContactCaroline DEMILY, MD PH
caroline.demily@ch-le-vinatier.fr0450915163
Backup ContactVéronique VIAL
veronique.vial@ch-le-vinatier.fr0437915531

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026